The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index.
Antithrombotic Therapy for Venous Thromboembolic Disease
Abstract
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following: for patients with objectively confirmed deep vein thrombosis (DVT), we recommend short-term treatment with subcutaneous (SC) low molecular weight heparin (LMWH) or, alternatively, IV unfractionated heparin (UFH) [both Grade 1A]. For patients with a high clinical suspicion of DVT, we recommend treatment with anticoagulants while awaiting the outcome of diagnostic tests (Grade 1C+). In acute DVT, we recommend initial treatment with LMWH or UFH for at least 5 days (Grade 1C), initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day, and discontinuation of heparin when the international normalized ratio (INR) is stable and > 2.0 (Grade 1A). For the duration and intensity of treatment for acute DVT of the leg, the recommendations include the following: for patients with a first episode of DVT secondary to a transient (reversible) risk factor, we recommend long-term treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For patients with a first episode of idiopathic DVT, we recommend treatment with a VKA for at least 6 to 12 months (Grade 1A). We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations (Grade 1A). We recommend against high-intensity VKA therapy (INR range, 3.1 to 4.0) [Grade 1A] and against low-intensity therapy (INR range, 1.5 to 1.9) compared to INR range of 2.0 to 3.0 (Grade 1A). For the prevention of the postthrombotic syndrome, we recommend the use of an elastic compression stocking (Grade 1A). For patients with objectively confirmed nonmassive PE, we recommend acute treatment with SC LMWH or, alternatively, IV UFH (both Grade 1A). For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulants are recommended after a first episode of VTE [28] to prevent recurrence [29][30][31][32].”
From Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome (2010) · cites this paper as [28]
Citations
Cites
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,528
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM
Barritt, D. W., & Jordan, S. C. (1960) · The Lancet · doi:10.1016/s0140-6736(60)92299-6 · Cited by 1,362
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O’Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,348
Levine, M., Gent, M., Hirsh, J., Leclerc, J. E., Anderson, D. R., Weitz, J. I., Ginsberg, J. S., Turpie, A. G. G., Demers, C., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,186
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G. E., Landefeld, S., & Kearon, C. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,129
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,105
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Research works printed but not linked: 7
- Hull, 2002, A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract], Blood, 100, 148a
- Hull, 2001, Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract], Thromb Haemost
- Hull, 2003, A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract], Thromb Haemost, P137a
- Prandoni, 2002, Below-knee compression stockings for prevention of the post-thrombotic syndrome: a randomized study [abstract], Pathophysiol Haemost Thromb, 32, 72
- Morl, 1986, Treatment of postthrombotic syndrome with a mixture of enzymes [in German], Therapiewoche, 36, 2443
- Massoure, 2000, Thromboses veineuses profondes des members supérieurs, J Mal Vasc, 25, 250
- Pegis, 1997, Thrombolyse in situ dans le traitement des thromboses veineuses d'effort du membre supérieur, J Mal Vasc, 22, 187
Cited by
Sorted by citations
Items 201–300 of 1,000
McCullagh, L., Tilson, L., Walsh, C., & Barry, M. G. (2009) · PharmacoEconomics · doi:10.2165/11313800-000000000-00000 · Cited by 73
Surie, S., Gibson, N. S., Gerdes, V. E. A., Bouma, B. J., van Eck‐Smit, B. L. F., Buller, H. R., & Bresser, P. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.12.016 · Cited by 72
New oral Xa and IIa inhibitors: updates on clinical trial results
Haas, S. K. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0108-7 · Cited by 72
“with these agents, particularly from large, controlled, randomized trials, has helped the development of evidencebased treatment guidelines such as those from the American College of Chest Physicians [1, 2] and has also helped define the place of these substances in such treatment guidelines [3].”
BackgroundEvidence-based approach to thrombophilia testing
Middeldorp, S. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0572-y · Cited by 70
“In general, after a first episode of venous thrombosis, 3–6 months of anticoagulant therapy is considered to have the optimal balance between the risk of treatment (bleeding) and the benefit (prevention of an extension or recurrence of venous thrombosis) [20].”
Atrial fibrillation in chronic non-cardiac disease: Where do we stand?
Lainščak, M., Dagres, N., Filippatos, G. S., Anker, S. D., & Kremastinos, D. T. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.078 · Cited by 69
Méan, M., Righini, M., Jaeger, K. A., Beer, J. H., Frauchiger, B., Osterwalder, J. J., Kucher, N., Lämmle, B., Cornuz, J., Angelillo‐Scherrer, A., et al. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0875-2 · Cited by 69
“The Villalta scale is well validated [28], has good to excellent inter-observer reliability [29], and is responsive to clinical change [31, 32].”
BackgroundThe Antiphospholipid Syndrome as a Neurological Disease
Arnson, Y., Shoenfeld, Y., Eisen, A., & Amital, H. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2009.05.001 · Cited by 69
Thromboprophylaxis in the intensive care unit: Focus on medical–surgical patients
Cook, D. J., & Crowther, M. A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c9e344 · Cited by 68
“However, the renal clearance of LMWH has led thrombosis experts to recommend that LMWH levels be monitored in patients with renal insufficiency (28), or that LMWH be avoided because of concerns about bioaccumulation and increased bleeding risk (29).”
BackgroundStein, P. D., & Matta, F. (2010) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2010.03.002 · Cited by 69
Lalonde, L., Martineau, J., Blais, N., Montigny, M., Ginsberg, J., Fournier, M., Berbiche, D., Vanier, M., Blais, L., Perreault, S., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.02.009 · Cited by 67
Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies
Falanga, A., & Rickles, F. R. (2007) · Hematology · doi:10.1182/asheducation-2007.1.165 · Cited by 67
Font, C., Farrus, B., Vidal, L., de Caralt, T. M., Visa, L., Mellado, B., Tàssies, D., Monteagudo, J., Reverter, J. C., & Gascón, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq720 · Cited by 67
“Anticoagulant therapy was prescribed by the treating oncologists according to current international recommendations at the time of the study [14,18] including clinical evidence available from the Randomized Comparison of”
MethodEffectiveness of Warfarin among Patients with Cancer
Rose, A. J., Sharman, J. P., Ozonoff, A., Henault, L. E., & Hylek, E. M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0228-y · Cited by 66
“In response to two randomized controlled trials that convincingly showed the superiority of low molecular weight heparin (LMWH) in the treatment of VTE among cancer patients, national expert consensus panels have recommended the use of LMWH for patients with VTE and cancer for at least the first 3 to 6 months of long-…”
BackgroundQuality of life after pulmonary embolism: the development of the PEmb-QoL questionnaire
Cohn, D. M., Nelis, E., Busweiler, L. A. D., Kaptein, A. A., & Middeldorp, S. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03341.x · Cited by 65
Gibson, N. S., Söhne, M., & Buller, H. R. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mcp.0000174231.70595.92 · Cited by 66
Anderson, J. A. M., & Weitz, J. I. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2011.09.007 · Cited by 67
Wichers, I. M., Nisio, M. D., Buller, H. R., & Middeldorp, S. (2005) · PubMed · Cited by 65
Guijarro, R., Montes, J., Sanromán, C., & Monréal, M. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.06.026 · Cited by 65
“Current guidelines from the American College of Chest Physicians, based on evidence from clinical trials, recommend that all patients with venous thromboembolism (VTE) be treated with heparin for at least 5 days as a bridge to longterm oral anticoagulant therapy for at least 3 months [1].”
BackgroundClinical relevance of distal deep vein thrombosis
Righini, M., & Bounameaux, H. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32830460ea · Cited by 65
“In spite of the reassuring data obtained from the outcome studies using proximal CUS, recent consensus conferences, including that of the American College of Chest Physicians (90) (ACCP) and the Australasian Society of Thrombosis and Haemostasis (91) still recommend to treat distal DVT with anticoagulants for a period…”
BackgroundResultD‐Dimer test in cancer patients with suspected acute pulmonary embolism
Nisio, M. D., Söhne, M., Kamphuisen, P. W., & Buller, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01323.x · Cited by 64
Kumar, D. K., Shewade, D. G., Loriot, M., Beaune, P. H., Balachander, J., Chandran, B. V. S., & Chandrasekaran, A. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1581-x · Cited by 63
Springmann, V., Schulman, S., Martineau, J., Stewart, J. A., Komari, N., McLeod, A. G., Strulovitch, C., Blostein, M. D., Faucher, J.-P., Gamble, G., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0169 · Cited by 63
“This improvement might be explained by more widespread uptake of guidelines relating to treatment of cancer-related VTE since Cook’s study, which started recruiting patients in 2004, the same year the 7th edition of the ACCP Guidelines were published, and the first time that LMWH monotherapy was recommended for cancer…”
BackgroundFranchini, M., Veneri, D., Salvagno, G. L., Manzato, F., & Lippi, G. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600552678 · Cited by 63
Magazzini, S., Vanni, S., Toccafondi, S., Paladini, B., Zanobetti, M., Giannazzo, G., Federico, R., & Grifoni, S. (2007) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2007.tb01776.x · Cited by 62
Thrombolysis for intravascular thrombosis in neonates and children
Raffini, L. J. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32831ef537 · Cited by 62
Kamphuisen, P. W., van Mierlo, P. J. W. B., Buller, H. R., & Söhne, M. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0753 · Cited by 62
Yunus, T. E., Tariq, N., Callahan, R. E., Niemeyer, D. J., Brown, O. W., Zelenock, G. B., & Shanley, C. J. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.08.057 · Cited by 61
Family History for Venous Thromboembolism and the Risk for Recurrence
Hron, G., Eichinger, S., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Stain, M., Gartner, V., & Kyrle, P. A. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.043 · Cited by 61
Cancer-Associated Thrombosis: Prevention and Treatment
Brose, K., & Lee, A. Y. Y. (2008) · Current Oncology · doi:10.3747/co.2008.177 · Cited by 60
Escala de riesgo de eventos adversos a corto plazo en pacientes con tromboembolia pulmonar
Uresandi, F., Otero, R., Cayuela, A., Cabezudo, M. Á., Jiménez, D., Laserna, E., Conget, F., Oribe, M., & Nauffal, D. (2007) · Archivos de Bronconeumología · doi:10.1157/13111348 · Cited by 60
Pulmonary Embolism After Combined Abdominoplasty and Flank Liposuction
Gravante, G. G., Araco, A., Sorge, R. P., Araco, F., Nicoli, F., Caruso, R. R. C., Langiano, N., & Cervelli, V. (2008) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181344470 · Cited by 60
Mapping the future: Organizational, clinical, and research priorities in venous disease
Meissner, M. H., Eklöf, B., Gloviczki, P., Lohr, J. M., Lurie, F., Kistner, R. L., Moneta, G. L., & Wakefield, T. W. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.08.049 · Cited by 59
Unprovoked recurrent venous thrombosis: prediction by D‐dimer and clinical risk factors
Baglin, T. P., Palmer, C. R., Luddington, R. J., & Baglin, C. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02889.x · Cited by 59
A pharmacologic overview of current and emerging anticoagulants.
Nutescu, E. A., Shapiro, N. L., Chevalier, A., & Amin, A. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.suppl_1.s2 · Cited by 59
Old and new anticoagulant drugs: A minireview
Mannucci, P. M., & Franchini, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.539250 · Cited by 58
“Pertaining to the treatment of acute venous thromboembolism, most guidelines recommend 5 – 10 days of subcutaneous LMWHs, which are more convenient than UH in the frame of the highly recommended outpatient setting of management (18,19).”
BackgroundInfluentialCharacterizing resolution of catheter-associated upper extremity deep venous thrombosis
Jones, M. A., Lee, D. Y., Segall, J. A., Landry, G. J., Liem, T. K., Mitchell, E. L., & Moneta, G. L. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.07.124 · Cited by 58
Warfarin and intracranial haemorrhage
Appelboam, R., & Thomas, E. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.05.001 · Cited by 55
Trends in vena caval interruption
Moore, P. S., Andrews, J. S., Craven, T. E., Davis, R. P., Corriere, M. A., Godshall, C. J., Edwards, M. S., & Hansen, K. J. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.09.067 · Cited by 57
Poli, D., Antonucci, E., Ciuti, G., Abbate, R., & Prisco, D. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02900.x · Cited by 57
Pulmonary Hypertension in Pregnancy: Critical Care Management
Bassily‐Marcus, A., Yuan, C., Oropello, J. M., Manasia, A. R., Kohli-Seth, R. D., & Benjamin, E. (2012) · Pulmonary Medicine · doi:10.1155/2012/709407 · Cited by 57
Factors Impacting Thromboembolism after Bariatric Body Contouring Surgery
Shermak, M. A., Chang, D. C., & Heller, J. A. (2007) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000256070.37066.7e · Cited by 57
Nieto, J. A., de Tuesta, A. M. D., Marchena, P. J., Tiberio, G., Todolí, J., Samperiz, A. L., & Monréal, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01167.x · Cited by 56
Heparin: From animal organ extract to designer drug
Middeldorp, S. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.07.004 · Cited by 56
Ethnic Differences in Warfarin Maintenance dose Requirement and its Relationship with Genetics
Schelleman, H., Limdi, N. A., & Kimmel, S. E. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1331 · Cited by 55
Clinical review: inferior vena cava filters in the age of patient-centered outcomes
Wang, S. L., & Lloyd, A. J. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.832951 · Cited by 54
Thromboembolic Therapies in Dogs and Cats: An Evidence-Based Approach
Lunsford, K. V., & Mackin, A. J. (2007) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2007.01.010 · Cited by 59
Endovascular Treatment Options in the Management of Lower Limb Deep Venous Thrombosis
Nazir, S. A., Ganeshan, A., Nazir, S., & Uberoi, R. (2009) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9662-z · Cited by 54
“However, it does not directly promote thrombus dissolution [ 7 ] and in patients with severe and extensive DVT, particularly acute iliofemoral disease, standard treatment alone may not be sufficient to resolve the acute emergency.”
BackgroundInferior Vena Cava Filters in the Management of Venous Thromboembolism
Crowther, M. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.015 · Cited by 54
Cook, L., Kahn, S. R., GOODWIN, J., & Kovacs, M. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02507.x · Cited by 54
Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism
Mismetti, P., Quenet, S., Levine, M. N., Merli, G. J., Decousus, H., Derobert, E., & Laporte, S. (2005) · CHEST Journal · doi:10.1378/chest.128.4.2203 · Cited by 54
Persijn, L., Decavele, A.-S., Schouwers, S., & Devreese, K. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.04.004 · Cited by 53
“because they need long-term anticoagulation to prevent recurrences [4].”
BackgroundThrombosis and the Antiphospholipid Syndrome
Ortel, T. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.462 · Cited by 53
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients.
Shaib, W. L., Deng, Y., Zilterman, D., Lundberg, B., & Saif, M. W. (2010) · PubMed · Cited by 52
Prandoni, P., Trujillo‐Santos, J., Surico, T., Valle, F., Piccioli, A., Monréal, M., & for the RIETE Investigators (2008) · Haematologica · doi:10.3324/haematol.13055 · Cited by 52
“According to the results of several randomized clinical trials,(4-7) international guidelines recommend the use of sub-therapeutic doses of low-molecular-weight heparins (LMWH) for the long-term prevention of recurrent VTE in all cancer patients.(8-10) However, in clinical practice many clinicians still administer VKA…”
BackgroundCharacteristics of the amiodarone–warfarin interaction during long-term follow-up
Lu, Y., Won, K. A., Nelson, B. J., Qi, D., Rausch, D. J., & ASINGER, R. W. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060415 · Cited by 52
Operative and peri‐operative considerations in the management of brain metastasis
Sankey, E. W., Tsvankin, V., Grabowski, M. M., Nayar, G., Batich, K. A., Risman, A., Champion, C. D., Salama, A. K. S., Goodwin, C. R., & Fecci, P. E. (2019) · Cancer Medicine · doi:10.1002/cam4.2577 · Cited by 51
Nieto, J. A., Bruscas, M. J., RUIZ‐RIBO, D., Trujillo‐Santos, J., Valle, R., Ruiz‐Giménez, N., & Monréal, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02188.x · Cited by 52
Technique of contemporary iliofemoral and infrainguinal venous thrombectomy
Comerota, A. J., & Gale, S. S. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.09.036 · Cited by 51
Critical Appraisal on the Utility of Echocardiography in the Management of Acute Pulmonary Embolism
Mookadam, F., Jiamsripong, P., Goel, R., Warsame, T. A., Emani, U. R., & Khandheria, B. K. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181c09443 · Cited by 50
“Once the goal INR of 2 to 3 is achieved, anticoagulation with parenteral agents can be stopped and the duration of therapy depends on the underlying risk.(64,67)”
BackgroundInfluentialImproved midterm outcomes for type A (central) pulmonary emboli treated surgically
Greelish, J. P., Leacche, M., Solenkova, N. S., Ahmad, R. M., & Byrne, J. G. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.12.030 · Cited by 50
How I treat venous thromboembolism in patients with cancer
Prandoni, P. (2005) · Blood · doi:10.1182/blood-2005-04-1508 · Cited by 50
“7 at risk of limb gangrene, where rapid venous decompression and flow restoration may be desirable (9,22).”
BackgroundInfluentialDelate, T., Witt, D. M., Ritzwoller, D. P., Weeks, J. C., Kushi, L. H., Hornbrook, M. C., Bowles, E. J. A., & Schrag, D. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0323 · Cited by 50
“VTE treatment in cancer patients are grade 1A evidence indicating a strong recommendation supported by high-quality evidence that is applicable to most patients [5, 6].”
BackgroundInfluentialPercutaneous Aspiration Thrombectomy in Treatment of Massive Pulmonary Embolism
Bayız, H., Dumantepe, M., Teymen, B., & Uyar, İ. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.06.014 · Cited by 50
Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review
Ferreira, C., Providencia, R. A., Ferreira, M. J., & Gonçalves, L. M. M. (2015) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20150142 · Cited by 57
Mechanisms of Disease: the impact of antithrombotic therapy in cancer patients
Petralia, G., Lemoine, N. R., & Kakkar, A. K. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0225 · Cited by 50
“The high frequency of VTE in cancer patients prompted the formulation of guidelines for both its prevention and treatment in this patient population”
BackgroundWittkowsky, A. K. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02073.x · Cited by 49
Thromboembolic Prophylaxis in Blunt Traumatic Intracranial Hemorrhage: A Retrospective Review
Depew, A. J., Hu, C. K. C., Nguyen, A. C., & Driessen, N. (2008) · The American Surgeon · doi:10.1177/000313480807401005 · Cited by 49
Management of deep vein thrombosis and prevention of post-thrombotic syndrome
Strijkers, R., ten Cate‐Hoek, A. J., Bukkems, S. F. F. W., & Wittens, C. H. A. (2011) · BMJ · doi:10.1136/bmj.d5916 · Cited by 49
Superficial thrombophlebitis of the legs: still a lot to learn
Decousus, H., & Leizorovicz, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01445.x · Cited by 48
Orlando, L. A., Wu, R. R., Beadles, C. A., Himmel, T. L., Buchanan, A. H., Powell, K. P., Hauser, E. R., Henrich, V. C., & Ginsburg, G. S. (2014) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31388 · Cited by 48
“Genetic counseling for comprehensive inherited thrombophilia risk assessment and management [Buller et al., 2004]”
BackgroundVenous thromboembolism and cancer: a systematic review
Arrais‐Rodrigues, C., Ferrarotto, R., Filho, R. K., Novis, Y. A. S., & Hoff, P. M. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0441-0 · Cited by 47
“Most studies confirmed that LMWHs are better alternative for long-term treatment of cancer-related VTE than warfarin [88, 104], strategy also recommended by some clinical guidelines [89, 105, 106].”
BackgroundNew Anticoagulant Agents: Direct Thrombin Inhibitors
Nutescu, E. A., Shapiro, N. L., & Chevalier, A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.005 · Cited by 48
van Weert, H. C. P. M., Dolan, G., Wichers, I. M., de Vries, C., ter Riet, G., & Buller, H. R. (2006) · PubMed · Cited by 48
Treatment of Cerebral Venous and Sinus Thrombosis
Masuhr, F., & upl, K. E. A. (2007) · KARGER eBooks · doi:10.1159/000111375 · Cited by 48
Arpaia, G., Cimminiello, C., Mastrogiacomo, O., & Gaudenzi, E. D. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328011f2dd · Cited by 48
The Use of Unfractionated Heparin and Low Molecular Weight Heparins in Pregnancy
Casele, H. L. (2006) · Clinical Obstetrics & Gynecology · doi:10.1097/01.grf.0000211958.45874.63 · Cited by 48
Guidelines and Performance Measures for the Prevention and Treatment of Venous Thromboembolism
Fanikos, J. R. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s6-a.14 · Cited by 47
Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients
Kim, H. S., Preece, S. R., Black, J. H., Pham, L. D., & Streiff, M. B. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.10.033 · Cited by 47
Cosmi, B., Legnani, C., Cini, M., Favaretto, E., & Palareti, G. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.12.024 · Cited by 47
Critical Care Issues in the Patient After Major Joint Replacement
Memtsoudis, S. G., Rosenberger, P., & Walz, J. M. (2007) · Journal of Intensive Care Medicine · doi:10.1177/0885066606297692 · Cited by 47
Pulmonary embolism: pathophysiology, diagnosis, treatment.
Kostadima, E., & Zakynthinos, E. G. (2007) · PubMed · Cited by 46
Harenberg, J. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.03.008 · Cited by 47
Karimi, M. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010078 · Cited by 46
Vena cava filters and inferior vena cava thrombosis
Corriere, M. A., Suave, K. J., Ayerdi, J. A., Craven, B. L., Stafford, J. M., Geary, R. L., & Edwards, M. S. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.048 · Cited by 46
Reporting Standards for Endovascular Treatment of Pulmonary Embolism
Banovac, F., Buckley, D. C., Kuo, W. T., Lough, D., Martin, L. G., Millward, S. F., Clark, T. W. I., Kundu, S., Rajan, D. K., Sacks, D., et al. (2009) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.09.018 · Cited by 46
Cerebral Vein Thrombosis Misdiagnosed and Mismanaged
Sasidharan, P. (2012) · Thrombosis · doi:10.1155/2012/210676 · Cited by 46
Uresandi, F., Otero, R., Cayuela, A., Cabezudo, M. Á., Jiménez, D., Laserna, E., Conget, F., Oribe, M., & Nauffal, D. (2007) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(07)60139-6 · Cited by 46
Anderson, J. A. M., & Weitz, J. I. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.07.004 · Cited by 46
Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm
Fengler, B. T., & Brady, W. J. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.10.021 · Cited by 46
Venous thromboembolism in elective operations: Balancing the choices
Qadan, M., Tyson, M., McCafferty, M. H., Hohmann, S., & Polk, H. C. (2008) · Surgery · doi:10.1016/j.surg.2008.06.019 · Cited by 46
Lyman, G. H., & Kuderer, N. M. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70029-3 · Cited by 45
“While the options for the appropriate treatment of a documented VTE are well recognized, the optimal method for preventing recurrent VTE (secondary prophylaxis) continues to be discussed [84].”
BackgroundClinical utility of a Web-enabled risk-assessment and clinical decision support program
Orlando, L. A., Wu, R. R., Myers, R. A., Buchanan, A. H., Henrich, V. C., Hauser, E. R., & Ginsburg, G. S. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.210 · Cited by 45
Extracorporeal Life Support: Physiological Concepts and Clinical Outcomes
Lim, H. S., Howell, N., & Ranasinghe, A. M. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.10.012 · Cited by 45
Inferior vena cava filters for recurrent thrombosis: current evidence.
Patel, S. H., & Patel, R. (2007) · PubMed Central · Cited by 45
An approach to the patient with retiform purpura
Wysong, A. S., & Venkatesan, P. (2011) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2011.01392.x · Cited by 45
“The consensus from the American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy is to treat patients with APS and a history of thrombosis with an indefinite duration of anticoagulation (66).”
BackgroundAssessing, preventing, and treating venous thromboembolism: Evidence-based approaches
Nutescu, E. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070108 · Cited by 44
Harkess, J. W., & Crockarell, J. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-03329-9.50010-6 · Cited by 44
Fluorescence enhancement of warfarin induced by interaction with β‐cyclodextrin
Vasquez, J. M., Vu, A., Schultz, J. S., & Vullev, V. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.188 · Cited by 43
Trujillo‐Santos, J., Herrera, S., Page, M. A., Soto, M. J., Raventós, A. A., Sánchez‐Martínez, R., & Monréal, M. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.06.032 · Cited by 43
Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism
Ibrahim, S. A., Stone, R. A., Obrosky, D. S., Geng, M., Fine, M. J., & Aujesky, D. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.20.2183 · Cited by 43
Metadata
- Authors
- Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 126
- Issue
- 3
- Pages
- 401S-428S
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2134355273
- Cited by
- 1,249
- References
- 208
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 32 · 2015: 25 · 2014: 25 · 2013: 41 · 2012: 54
- FWCI
- 121.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- venous thromboembolism, antithrombotic therapy, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, vitamin K antagonists, anticoagulation duration, post-thrombotic syndrome, compression stockings, thrombolysis, thromboprophylaxis
- MeSH terms
- Fibrinolytic Agents, Heparin, Heparin, Low-Molecular-Weight, Humans, Long-Term Care, Pulmonary Embolism, Vitamin K, Randomized Controlled Trials as Topic, Evidence-Based Medicine, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
